Five things for pharma marketers to know: Tuesday, December 6, 2016

Prices of Viagra and Cialis triple since 2010; AstraZeneca's Tagrisso slows lung-cancer progression compared to chemo; Novo Nordisk to limit price increases

Matt Brown leaves Guidemark Health after merger falls through

The agency is owned by High Road Capital Partners. Sophy Regelous, the company's chief operating officer, will now lead the agency.

The 2017 pipeline report: What to know about next year's launches

The 2017 pipeline report: What to know about next year's launches

Here's a look at 100 experimental therapies in late-stage clinical trials.

Mylan CEO defends EpiPen strategy, questions pricing model in the U.S.

Mylan CEO defends EpiPen strategy, questions pricing model in the U.S.

Heather Bresch's appearance at industry summit came after she declined to attend a congressional hearing scheduled for the same day.

Rock Health's Bill Evans on finding a career with meaning

Rock Health's Bill Evans on finding a career with meaning

The Roche veteran says that people who work in digital health need to touch others in a meaningful way.

Five things for pharma marketers to know: Monday, December 5, 2016

Five things for pharma marketers to know: Monday, December 5, 2016

The FDA approves new indication for Jardiance; Novartis' CAR-T therapy eliminates leukemia in 82% of patients in trial; doctors report risks associated with immunotherapy

Prescription drug spending rises 9% in 2015, to $324 billion

Prescription drug spending rises 9% in 2015, to $324 billion

However, the rate of drug spending slowed compared to last year, according to an analysis by the CMS.

As users move to mobile, Google says they made 200 million queries for info about cancer drugs

As users move to mobile, Google says they made 200 million queries for info about cancer drugs

The search-engine giant says that one in 20 online searches are related to healthcare, and more users are using mobile to consume media.

Five things for pharma marketers to know: Friday, December 2, 2016

Five things for pharma marketers to know: Friday, December 2, 2016

Regeneron and Pfizer CEOs argue about the industry's reputation; Mylan CEO defends the EpiPen; Pfizer and IBM to partner on cancer immunotherapies

Five things for pharma marketers to know: Thursday, December 1, 2016

Five things for pharma marketers to know: Thursday, December 1, 2016

Valeant doesn't plan to offload Salix; heart docs back Califf as commish; Saunders says pricing issues aren't affected by election

House passes 21st Century Cures Act that would allow some off-label sharing

House passes 21st Century Cures Act that would allow some off-label sharing

The bill includes two provisions that would address drugmakers' calls for clarity on sharing off-label information with payers and regulators.

MM&M's top 5 stories in November 2016

MM&M's top 5 stories in November 2016

How VR, nanotechnology, and 3D printing could improve the value of healthcare; 100 experimental therapies in late-stage clinical trials; Kite Pharma plans "controlled" launch of CAR-T therapy

Five things for pharma marketers to know: Wednesday, November 30, 2016

Five things for pharma marketers to know: Wednesday, November 30, 2016

Astellas Pharma is searching for Xtandi successor; Novo Nordisk says Tresiba is safer than Lantus; Pfizer awards Nexium account to Grey

Lilly's branded app for Trulicity looks to address adherence

Lilly's branded app for Trulicity looks to address adherence

Companies such as Eli Lilly and Medtronic have launched branded apps for their products, but experts say they don't make sense for all medicines.

Lawmakers cut CME exemption from 21st Century Cures Act

Lawmakers cut CME exemption from 21st Century Cures Act

The bill includes provisions to investigate the usefulness of off-label information but will no longer exempt drugmakers from reporting CME payments.

How Duchesnay USA got over the Kardashian marketing bump

How Duchesnay USA got over the Kardashian marketing bump

The drugmaker still views Instagram as a viable marketing platform, however.

Five things for pharma marketers to know: Tuesday, November 29, 2016

Five things for pharma marketers to know: Tuesday, November 29, 2016

Trump selects Price as head of HHS; Warren criticizes 21st Century Cures; GSK CEO says companies will have to get used to making less money

Gilead's Meyers on making deals and finding unmet patient needs

Gilead's Meyers on making deals and finding unmet patient needs

The drugmaker's new EVP of worldwide commercial operations also talks about tackling medication access, product launches, and starting a commercial team from scratch.

Five things for pharma marketers to know: Monday, November 28, 2016

Five things for pharma marketers to know: Monday, November 28, 2016

J&J in talks to buy Actelion; Novo Nordisk pulls ads on Breitbart News; Takeda to market Ninlaro in Europe

U.S. marketers spend slightly less on digital engagement with docs than China

U.S. marketers spend slightly less on digital engagement with docs than China

A new survey found that U.S. pharma marketers prefer using social media and mobile apps to reach healthcare providers.

Agency Spotlight

Featured Listings

LevLane

LevLane

Featured Work: Kennedy Health brings sophisticated healthcare to South Jersey, and we wanted this ...

OPINION

Email Newsletters